Telomir Pharmaceuticals (NASDAQ: TELO) announced positive preclinical results demonstrating its lead compound, Telomir-1, significantly reduced react ...
Telomir Pharmaceuticals (TELO) announced results from its recent preclinical studies conducted in human retinal cell lines. These studies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback